Article Versions Notes

Jeon HJ, Lim SY, Jeong H, Yoon SJ, Kim H, Shin SH, Heo JS, Han IW. Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Biomedicines. 2023; 11(8):2302. https://doi.org/10.3390/biomedicines11082302

Jeon, Hyun Jeong, Soo Yeun Lim, HyeJeong Jeong, So Jeong Yoon, Hongbeom Kim, Sang Hyun Shin, Jin Seok Heo, and In Woong Han. 2023. "Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer" Biomedicines 11, no. 8: 2302. https://doi.org/10.3390/biomedicines11082302

Jeon, H. J., Lim, S. Y., Jeong, H., Yoon, S. J., Kim, H., Shin, S. H., Heo, J. S., & Han, I. W. (2023). Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Biomedicines, 11(8), 2302. https://doi.org/10.3390/biomedicines11082302